Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436071 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 248
- Enrollment target
NCT01436071 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 248 participants.
The verdict
NCT01436071, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 248 participants
- Enrollment target
Study Summary
A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids
Interventions
- DRUG Placebo
- DRUG Fluticasone furoate 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436071
The ClinicalTrials.gov registry entry for NCT01436071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01436071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01436071 about?
NCT01436071 is a clinical study titled "Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma". A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids
What is the current status of trial NCT01436071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 248 participants. The study started on 2011-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01436071?
The interventions under investigation include: Placebo (DRUG), Fluticasone furoate 50mcg (DRUG).
Who is sponsoring clinical trial NCT01436071?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.